Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JUST IN: $ALXN 2 Top Pharma Stocks to Buy Right Now
Most of us don't choose when to be sick, what illness will befall us, or what medicine we will take to recover. Thankfully, the pharmaceutical industry -- which is responsible for developing life-saving drugs -- never sleeps. While this sector has not escaped the COVID-19-induced economic c...
In case you are interested ALXN - 2 Top Pharma Stocks to Buy Right Now
JUST IN: $ALXN Labor Day Special: 3 Deep-Discount Stocks to Buy Now
Every year since 1894, the first Monday in September has been a federally recognized holiday to "celebrate the social and economic achievements of American workers," according to the U.S. Department of Labor. However, Labor Day has taken on a completely different feel in 2020. The coronav...
In case you are interested ALXN - Labor Day Special: 3 Deep-Discount Stocks to Buy Now
ALXN SEC Admin. Proceeding: Cease and Desist Order:
https://www.sec.gov/litigation/admin/2020/34-89214.pdf
This Pharma is in due diligence with another one right now, so I heard. Rumor has it, Alexion is being bought.
1 billion in share buy back!!!! YES!
LetterPenny, now that’s what I am talking about brother!
LetterPenny... did you see they got approval?... hopefully that will offset the debt of the recent acquisition.
Absolutely agree a good buy at this market price
Alexion puts in stalking bid for Bertilimumab. The next big thing. Maybe they get a great deal.
** PENDING BUYOUT! LOAD UP FOLKS!!!!
RUMOR HAS IT that recent events of moving to Boston is due to a pending buyout! This is a strategic move to tighten the pursestrings and clean up the books!
MY SOURCES HAVE ALWAYS BEEN ACCURATE!
ALEXION TRIMMING THE FAT
SEE? I wasn't lying!
They are laying off 50% of their workforce, getting rid of 60% of their compounds, consolidating building and moving to Boston, all to save shareholders money.
This will initially be a HUGE hit to the PPS. We should see a record $70.00 PPS.
However, it really should bounce back immediately up to the $180's in my opinion, as this will become a more leaner company with better profit margins.
Apparently, Soliris drug sales are increasing. But..
https://alphastreet.com/bite/4dac307
But how long can this company run on this? Given, the company has also announced that it is reducing the R&D expense for the year.
LAYOFFS ARE LOOMING!
Stocks will be affected - time is ticking! Dump while you can, folks!
CASH IN WHILE IT'S ON A HIGH!
https://seekingalpha.com/news/3273272-alexion-sputtering-kanuma-launch-write-looming
In this seeking alpha article, it clearly indicates where this company is heading. CEO Ludwig Hantson, is notorious for going into Pharmas, trimming the fat and preparing it for a buyout. That executive team that he brought in? They're all a part of the buyout team he formed in the other companies he spearheaded.
As you can see here, he's trimming the fat and I suspect he's getting rid of Alexion's metabolical area which has proven to be disastrous to the company. The article mentions Kanuma being written off, but I suspect that Strensiq will be a part of the deal as well, as both drugs has performed poorly in sales. The didn't include Strensiq as not to alarm the shareholders, but clearly that drug's sales performance is poor as well.
This means Alexion will become a one-hit-wonder again which will result in another wave of massive layoffs which I can only imagine will come before August in my opinion.
I don't even think there's anything else in the company's pipeline that's worthy at this point, is there?
The question is, who's buying them out?
good ill buy more
OH WAIT UNTIL NEXT WEEK FOLKS!
I SMELL $80 BUCKS A SHARE! COUNTDOWN BEGINS!
Up up and away hey, starting next week
LOL!
Delusional.
You're all in for a rude awakening. Sit back and watch :)
Honestly all that I care about is the fact that Martin Shkreli is in $ALXN balls deep. Hes started numerous pharmaceutical companies and created pharmaceuticals himself. Not many people know the space better than he does, and not gonna pretend like any of my own DD will have a spec of impact. He believes the company is worth 2 to 3 times its current price. See you guys at $200.00
I thought message boards were here to share information related to these stocks.
Guess at ALXN you guys take it too personal.
Its just a stock dude, is there a reason for your anger?
Sure, whatever makes you sleep at night.
So sorry your stocks are under water that you have to pump a stock :(
LOL
most people online claiming to live in $4m homes live in their parents basement.
But okay, the bet is on
I will mortgage my home and bet 4M in cash that it will NOT be approved (if at all) for 3 years.
You're delusional and don't know the first thing about it. Your field is investments. You may be seated.
Quote- "“I have never seen the clinical responses that I’ve observed in IgA nephropathy patients treated with OMS721,” stated Geoffrey Block, M.D., Director of Clinical Research at Denver Nephrology and Principal Investigator of the trial. “All of these patients had significant renal impairment when they entered the trial and each patient dramatically improved. The improvements in these patients continued to increase after the end of treatment and persisted following completion of the trial. As an active clinical investigator, given the strength of these data, I am working hard to move this promising drug through the clinical trial process.”--
That's far fetched and will not happen.
This is 2 - 3 years out. That's wishful thinking and just a ploy for you to pump their stock.
Alexion is tanking on due to their own mistakes - their biggest was acquiring Synageva which is bleeding them dry.
The drug you mentioned, if approved will be the nail on the coffin - as their drug requires a 24 hour drip at a high price tag.
Alexion's PPS should hover around 55 - 60 at the most. More layoffs are on the way, you'll see.
Fish out of water have a better chance of surviving than ALXN!
FDA sugest them to file for BTD , due to the impressive data from phase 2
Could go real fast for OMER
Don't spread lies.
They are at least 2-3 years away from being approved. Just entered Phase 3.
R&D takes 10 years.
http://www.omeros.com/images/pipeline-4-6-2017-large.png
They always say buy before leaving a sinking ship,
They know omeros has a better product , ready to be approved
newbs sellingggg. big $$ to be made here!
Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2017?
24 equities research analysts have issued 1 year target prices for Alexion Pharmaceuticals' stock. Their predictions range from $120.00 to $221.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $165.36 in the next twelve months.
Adam Feuerstein, martin and goldman say buy its a rare opportunity plus myself. you dont get better picks.
With nothing good in their pipeline and their failed projection in sales, you've been sold a bill of goods!
I can't wait to check back with you in 6 months!
Have fun!
see you at $200 in 6 months BRO
I know, peanut. Rare to buy into a failing company. Good for you! Congrats!
no i just started buying last week. and will add. it is a rare opportunity.
Sure :)
Sorry you're under water.
$ALXN lol green close coming!! this is going back to 200$ THIS IS THE NEXT ABBV
ASK THE CEO FOR A HEAD COUNT OF EMPLOYEES!
You may be surprised!
ASK THE CEO ABOUT SALES!!!
You may be surprised!
ASK THE CEO ABOUT STABILITY!!!
You may be surprised!
SELL YOUR SHARES WHILE THEY ARE STILL IN THE $90'S, FOLKS!
Let's focus, peanut.
The only difference between Alexion and the Titanic is that the Titanic had a band as it was sinking.
You'll see when it hits $60 PPS. You'll be wishing you sold now.
Sure. and their batteries last for weeks right? way better then Teslas batteries and they are on the otc and nobody heared of them. it is some magical chinese investor making 10 times better batteries then tesla.. things like that dont happen irl. Technology is with with universities and the big boys etc not at some Chinese garage.
I made over 680K on that stock. I've done well, thanks.
*Pats you on the head*
you just keep buying dolv.thinking it is the next tesla right? dream in son.
You're going to put weight into the words of Martin Shkreli? LOL
If anyone reads that - they will side with me. Martin is a shyster!
Newb martin Shkreli and goldman both say it is a buy and you think it is a sell. it is undervalued look at the numbers. and not for 1 hour. study them 1 week. strong buy
Stop pumping this stock.
The demise of this company was the purchase of Synageva and the bloated price they paid. They never recovered. Also the failed sales projections on their drugs.
They've been incorrect on all profit projections and their company value has been cut in half.
That being said, the stock price should be too. This stock price should be more in line with $60.00 per share.
Look at their layoffs. They are dumping people left and right. They received a huge tax break from the governor for staying in Connecticut if they create jobs, but that's not happening.
And you'll see more layoffs to come. I'd like to know how they're not reneging on the governor's agreement of creating more jobs.
You must own stock in this and now underwater.
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
155
|
Created
|
05/20/08
|
Type
|
Free
|
Moderators |
http://www.alexionpharm.com/
http://finance.yahoo.com/q/ks?s=ALXN
Alexion Pharmaceuticals, Inc., a biotechnology company, develops and delivers life-changing drug therapies for patients with serious and life-threatening medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. The company markets Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder in the United States and Europe. It also is evaluating other potential indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, it is developing antibody product candidates targeting the treatment of patients with severe unmet medical needs. The company's drug programs comprise DC-SIGN Mab, a cancer Vaccine; Eculizumab (intravitreal) for age-related macular degeneration; and Eculizumab (intravenous) for myasthenia gravis and multifocal motor neuropathy, which are under preclinical development stage; CD200 Mab for the treatment of chronic lymphocytic leukemia and multiple myeloma under Phase I clinical trial; and Eculizumab (intravenous) under Phase I/II clinical trial for the treatment of asthma. . Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut.
Headquartered in Cheshire, Connecticut, Alexion employs more than 700 people around the world. In addition to our corporate headquarters, Alexion’s facilities include a manufacturing plant in Smithfield, Rhode Island, EMEA (Europe, Middle East & Africa) regional headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Tokyo, Japan, Sydney, Australia, São Paulo, Brazil, Ontario, Canada and other countries. The company is also expanding its reach in Latin America, the Middle East and Africa.
Alexion’s global presence reflects the approval of Soliris for the treatment of patients with PNH in the United States, 29 European countries, Australia, Canada and other countries. The company is working toward seeking regulatory approval in other countries of Asia and South America.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |